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Mouse embryonic stem (ES) cells are the in vitro
counterparts of an in vivo population of cells, known as
the epiblast, that are specific to the early embryo [1–3].
Epiblast cells are pluripotent, which means that an
individual cell can give rise to all cell types of the
foetus. ES cells retain the developmental identity and
potential of the epiblast even after prolonged culture.
This has been shown conclusively by their complete
integration into a developing embryo after being
reintroduced into the blastocyst [4]. ES cells 
can efficiently colonize the germ line, resulting in
chimaeric animals. These produce functional
gametes, which allows ES cells to be used as vehicles
for introducing sophisticated genetic modifications
into mice [5]. ES cells can also undergo multilineage
differentiation in vitro and produce a range of
well-differentiated progeny [6,7]. Currently there is
considerable interest in the prospect of exploiting this
potential in analogous human pluripotent cells [8] to
generate specific, differentiated types of cell for drug
development, for therapies based on cell replacement,
and for delivering gene therapies.
Less attention has been paid to the unusual
proliferative properties of ES cells [9–11]. ES cells are
derived without the intervention of any immortalizing
agent, do not undergo either crisis or senescence, and
retain a diploid karyotype. They proliferate without
apparent limit [12] and can readily be propagated
clonally. They can multiply in the absence of serum
and are not subject to contact inhibition or anchorage
dependence. In fact there is no known means of
inducing cell-cycle arrest and quiescence in ES cells.
Apart from the normal karyotype, these are features
that are typical of transformed cells and, indeed,
ES cells are tumorigenic. In contrast to their
behaviour when introduced into the early embryo,
they produce teratocarcinomas when injected into
adult mice, Thus ES cells can be considered as
conditional tumour cells.
Embryonic stem cells undergo symmetrical
self-renewal – that is, they produce two identical 
stem cell daughters when they divide. Self-renewal
entails the suppression of differentiation during
proliferation. Here we review current data on the
regulation of ES cell self-renewal by signalling
networks and discuss the relationship between
cell-cycle control and the retention of pluripotency.
Cytokine-dependent activation of STAT3 drives ES cell
self-renewal
The propagation of mouse ES cells is dependent on
the presence of leukaemia inhibitory factor (LIF) 
or related cytokines that can activate signal
transduction from cell-surface receptors [13–15]. 
LIF can be provided by a feeder layer of embryonic
fibroblasts [16,17] and/or as a recombinant protein.
LIF engages a heterodimeric receptor complex
consisting of two related cytokine receptors, 
LIF receptor (LIFR) and gp130 [18]. This complex
activates associated Janus-associated (JAK) tyrosine
kinases that phosphorylate the receptor chains. The
phosphorylated tyrosines then act as docking sites for
proteins containing Src homology 2 (SH2) domains
that might themselves be phosphorylated by the
JAKs (Fig. 1).
The signal transducer and activator of
transcription (STAT) family of transcription factors
Pluripotent mouse embryonic stem (ES) cells can be expanded in large
numbers in vitro owing to a process of symmetrical self-renewal. Self-renewal
entails proliferation with a concomitant suppression of differentiation.
Here we describe how the cytokine leukaemia inhibitory factor (LIF) sustains
self-renewal through activation of the transcription factor STAT3, and 
how two other signals – extracellular-signal-related kinase (ERK) and
phosphatidylinositol-3-OH kinase (PI3K) – can influence differentiation and
propagation, respectively. We relate these observations to the unusual
cell-cycle properties of ES cells and speculate on the role of the cell cycle 
in maintaining pluripotency.
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bind receptor phosphotyrosines and are key
substrates for JAKs. Phosphorylation of STATs
promotes their dimerization through reciprocal
interactions between an SH2 domain and
phosphotyrosine. This triggers their translocation 
to the nucleus and their binding to target sites on
DNA. In ES cells, LIF predominantly activates
STAT3 [19].
Recruitment and activation of STAT3 is essential
for self-renewal of ES cells [19,20], and expression of
an inhibitory STAT3 mutant in ES cells forces
differentiation [19,21]. Studies using a chimaeric
STAT3 molecule that can be activated directly by
estradiol (Fig. 1) indicate that STAT3 activation is 
not only necessary but might be sufficient to block
differentiation [22]. Activation of this chimaeric
molecule sustains ES cell self-renewal without the
addition of LIF. It should be noted, however, that
these experiments were carried out at moderate to
high densities of cells in the presence of serum, which
might provide additional signals that support ES cell
viability and/or proliferation [22].
ERKs antagonize ES cell self-renewal
Signalling downstream of gp130 is not limited to
activation of STAT3 but includes stimulation of the
Ras/mitogen-activated protein kinase (MAPK)
pathway. The ERK MAPKs p42 and p44 regulate
many different cellular responses in somatic cells 
and have particularly well-documented roles in
proliferation and differentiation. In its simplest 
form, the ERK pathway is engaged through the
recruitment of a complex containing the Grb2 adaptor
and Sos guanine-nucleotide-exchange factor to
activated receptors. Localization of Sos at the
membrane promotes activation of Ras. This initiates
a cascade of transphophorylations involving Raf and
MAPK kinase (MEK) kinases that culminates 
in activation of ERK [23] (Fig. 2). Active ERKs
phosphorylate cytoplasmic targets and also 
undergo nuclear translocation, which enables 
them to modulate the activities of transcriptional
regulators such as Elk, Ets, Myc and the serum
response factor (SRF).
Receptor recruitment of the Grb2–Sos complex 
can be indirect. In the context of LIFR–gp130, a key
intermediate in this recruitment is the protein
tyrosine phosphatase SHP-2. Tyrosine phosphorylation
of SHP-2 generates binding sites for Grb2. SHP-2 also
associates with the scaffold protein Grb2-associated
binder protein 1 (Gab1). This protein recruits the 
lipid kinase PI3K and, by binding the resulting
phospholipid products through its N-terminal
pleckstrin homology (PH) domain, stabilizes the
association of the SHP-2–Gab1–Grb2 complex at the
membrane and potentiates coupling to Ras [24].
In ES cells, eliminating the SHP-2 binding site
from a chimaeric gp130 receptor blocks coupling to
the Ras pathway but enhances the self-renewal
response [25]. This effect is partly due to the elimination
of a negative feedback effect on JAK activity [26],
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Fig.1. LIF-dependent activation of STAT3 blocks ES cell differentiation
and promotes self-renewal. Leukaemia inhibitory factor (LIF) stabilizes
the association of LIFR and gp130 cytokine receptors. Resultant
activation of receptor-associated JAK kinases causes the recruitment,
tyrosine phosphorylation and dimerization of STAT3. The STAT3
dimers then translocate to the nucleus, where they control the
transcription of genes regulating self-renewal. The importance of
STAT3 is confirmed by the demonstration that a conditionally regulated
form of the transcription factor STAT3ER can, when activated,
substitute for LIF addition (boxed insert). Abbreviation: ER, ligand
binding and dimerization domain of the oestrogen receptor.
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Fig. 2. Reduction in Ras/MEK/ERK signalling promotes ES cell
self-renewal. Binding of the adaptors Grb2 or SHP-2 couples
cell-surface receptors to the Ras/Raf/MEK/ERK signalling pathway.
Interference with this pathway by mutation of Grb2 or Shp2, by
inhibiting the activation of MEKs with the small-molecule inhibitors
PD98059 and UO126, or by dephosphorylating ERKs by mitogen
activated protein kinase phosphatase 3 (MKP-3), limits the
differentiation of ES cells and promotes self-renewal. 
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which is independent of Ras. But specific attenuation
of ERK signalling – either by pharmacological
inhibition of MEK activity or by forced expression 
of ERK phosphatases – also facilitates self-renewal 
by reducing differentiation ([25] and T. Burdon,
unpublished). Notably, inhibition of ERK does not
replace the requirement for activation of STAT3 
but rather enhances the actions of STAT3, although 
it is not clear whether this effect is direct or indirect.
The indications that ERK activation has a
pro-differentiation effect and is antagonistic to 
ES cell self-renewal are corroborated further by
genetic disruption of either Grb2 [27] or Shp2 [28],
which results in impaired differentiation (Fig. 2).
Reintroducing either a Grb2–Sos chimaera or an
activated form of Ras into Grb2–/– ES cells restores
normal differentiation [27].
ERK activity reflects the input not only of gp130
cytokines but also of ligands that stimulate Ras
through receptor tyrosine kinases and other
cell-surface receptors. The overall balance of
conflicting activation of STAT3 and ERKs might
determine the efficiency of ES self-renewal [29].
PI3K signalling in ES cell propagation
An increased amount of 3′-phosphorylated
phosphoinositides is frequently associated with
growth factor and cytokine signalling pathways. 
This increase occurs through receptor-mediated
translocation of PI3K to the cell membrane. The PI3K
products phosphatidylinositol (3,4)-bisphosphate
[PtdIns(3,4)P2] and phosphatidylinositol
(3,4,5)-trisphosphate [PtdIns(3,4,5)P3] are ligands 
or the PH domains of several signal transducers,
including the serine/threonine kinases,
phosphoinositide-dependent kinase 1 (PDK1) and
protein kinase B (PKB)/Akt. Coordinate localization
of these lipid-bound kinases at the membrane
facilitates PDK1-mediated phosphorylation of PKB,
which then modulates the activity of key regulators of
apoptosis, the cell cycle and cellular metabolism in
various types of cell [30]. The PI3K signalling
pathway is also linked to cellular transformation. 
The tumour suppressor PTEN is a lipid phosphatase
that functions as a negative regulator of the PI3K
pathway by removing the phosphate from the
3′ position of 3-phosphoinositides.
The PI3K signalling pathway has been implicated
in ES cell propagation through studies on Pten–/– ES
cells. These cells have both enhanced viability and an
increased rate of cell proliferation [31]. Improved cell
survival is correlated with elevated amounts of
PtdIns(3,4,5)P3, enhanced phosphorylation of PKB,
and inactivation of the pro-apoptotic protein Bad. An
accelerated transit through G1 seems to be caused by
an increase in the rate of degradation of the p27Kip1
inhibitor of cell-cycle progression (Fig. 3). Notably, the
increase in the rate of cell division is more marked in
Pten–/– ES cells than in Pten–/– fibroblasts, which
suggests that PI3K-dependent signals could be
relatively more significant in regulating the cell cycle
of ES cells than in regulating that of fibroblasts.
The PI3K-dependent signals that influence the
proliferation and survival of ES cells have not been
defined. Although PKB might seem to be a likely
candidate, ES cells lacking the upstream activator
PDK1 are viable with no reported proliferation defect
[32]. They show negligible activation of PKB and also
fail to activate other targets of PDK1, including
p90 Rsk and p70 S6 kinase. These results raise the
possibility that PI3K can influence ES cell growth
through a pathway that is not dependent on
PDK1/PKB. The PKB-related protein serum and
glucocorticoid-induced kinase 1 (SGK) might fulfil
this role [33,34]. Alternatively, the PI3K/PDK1
pathway might have a supportive, but dispensable,
role in self-renewal.
Unique signalling adaptors in ES cells
Embryonic stem cells express a variant of
SH2-containing inositol 5′-phosphatase (SHIP) that
lacks the SH2 domain [35]. This enzyme normally
removes 5′ phosphates from the lipid products of
PI3K, and in some systems it inhibits the activation of
downstream signals such as PKB. The variant
expressed in ES cells is reported to bind the adaptor
protein Grb2, but remains unphosphorylated and
does not associate with the docking protein Shc [35]. 
Embryonic stem cells also specifically express
large amounts of a variant Gab1 molecule. This
protein lacks the N-terminal PH domain, which
TRENDS in Cell Biology 
s-SHIP?
PI3K PTEN
PIP3
p27
ES cell-cycle progression
PKB
PDK1
ES cell survival
Adaptor
Gab1?
Fig. 3. PI3K-dependent signals promote ES cell survival and cell-cycle
progression. Localization of phosphatidylinositol-3-OH kinase (PI3K) at
the plasma membrane, through a receptor-associated adaptor protein
such as Gab1, increases the amounts of 3′-phosphorylated inositol
lipids [PtdIns(3,4,5)P3]. These molecules colocalize with the
phospholipid-binding kinases PDK1 and PKB, and promote the
activation of PKB by PDK1. In ES cells, potentiation of PI3K signalling by
mutation of the PI3K antagonist PTEN, a 3′-phosphate lipid phosphatase,
enhances ES cell survival and increases proliferation rate by
suppressing activity of the cell-cycle inhibitor p27kip1. The report of a
novel lipid phosphatase (s-SHIP) expressed in ES cells and
haematopoietic stem cells is tantalizing; however, a role for this
molecule in stem cell signalling has yet to be established. 
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results in attenuated coupling to the Ras/ERK
cascade (T. Burdon and A. Smith, unpublished).
The presence of these novel isoforms indicates that
the signalling circuitry in ES cells is likely to differ
from that in other cell types, although the functional
significance of these molecules is yet to be determined.
Cell-cycle control differs in differentiated cells and
ES cells
Proliferation of differentiated mammalian cells is
controlled primarily by regulating the progression
through G1 phase and entry into S phase. The
retinoblastoma (RB) protein and its relatives p107
and p130 are essential components in the control of
the G1/S transition (Fig. 4). The activity of RB is
regulated by phosphorylation: hypophosphorylated
(G1-specific) RB inhibits the expression of genes that
are required for entry into S phase by sequestering
the E2F family of transcription factors. During
progression through G1, RB is phosphorylated
sequentially by complexes of cyclins and cyclin-
dependent kinases (CDKs). Phosphorylation by
cyclin D/CDK4 or cyclin D/CDK6 induces a partial
release of E2F, which is sufficient to activate
transcription of the cyclin E and the cdc25A genes. The
cdc25A phosphatase removes inhibitory phosphates
from CDK2, and the resulting cyclin E/CDK2 complex
then completes RB phosphorylation, leading to full
release of E2F, activation of target genes and entry
into S phase [36–38]. 
A second pathway involves the c-myc proto-
oncogene, which directly stimulates transcription 
of the genes that encode cyclin E and cdc25A to
generate cyclin E/CDK2 kinase [38] (Fig. 4). The Myc
and the RB/E2F pathways are now thought to be two
parallel and cooperative G1/S control pathways that
converge on cyclin E/CDK2 kinase – the activity 
of which determines entry into S phase [38].
Mutations in either or both pathways are frequently
encountered in cancers [39,40], reflecting their
fundamental role in controlling the cell cycle. The
tumour suppressors p16ink4a and p27kip1 are inhibitors
of cyclin D/CDK4 or cyclin D/CDK6 and cyclin
E/CDK2, respectively. They are activated in response
to various growth inhibitory signals, including
senescence, contact inhibition and terminal
differentiation [41].
Embryonic stem cells have a short G1 phase of
roughly 1.5 h during which hypophosphorylated RB is
virtually undetectable [9]. Thus, RB is likely to be
rephosphorylated immediately after mitosis in
STAT3
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Fig . 4. Models of cell-cycle control in differentiated cells and embryonic stem (ES) cells. (a) The
RB/E2F and Myc pathways function in parallel to control accumulation of cyclin E/CDK2 and entry into
S phase in differentiated cells. (b) Hypothetical pathways for regulating the accumulation of cyclin
E/CDK2 in ES cells. The broken line indicates that cyclin D/CDK4 or cyclin D/CDK6 kinase activity
seems to be dispensable in activating RB.
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ES cells, in contrast to differentiated types of cell. 
An important issue therefore is whether ES cells are
subject to G1 regulation by RB or other members of the
RB family, or whether RB is functionally inactivated
by constitutive hyperphosphorylation. In addition to
RB, ES cells express p107 [42] but not p130 [43]. 
But much evidence supports the notion that the
RB pathway does not regulate the ES cell cycle. 
First, ES cells are refractory to the growth
inhibitory activity of p16ink4a [10]. Resistance to
growth inhibition mediated by p16ink4a is a common
feature of cancer cells in which the RB pathway is
disrupted [44,45]. Withdrawal of LIF and subsequent
differentiation is accompanied by sensitization to
growth inhibition mediated by p16ink4a, which
indicates that RB control of G1 is imposed during
differentiation [10]. 
Second, inactivating disruptions in all three 
genes of the RB family [p107–/–p130–/–Rb–/– triple
knockout (TKO) cells] do not seem to compromise the
proliferation of ES cells but do reduce differentiation
in teratocarcinomas [46,47]. This indicates further
that RB dependence is acquired only as ES cells
undergo differentiation.
Last, ES cells share striking similarities in
proliferative behaviour with TKO embryonic
fibroblasts. Both TKO MEFs and ES cells fail to arrest
in G1 at confluency [46,47]. In normal fibroblasts this
phenomenon is accompanied by increased amounts of
p27kip1, decreased amounts of cyclin D1 and an
accumulation of hypophosphorylated RB, which leads
to G1 arrest [48]. ES cells and TKO MEFs also escape
replicative senescence and are immortal [46,47]. 
In other cells, replicative senescence and G1 arrest
are associated with an accumulation of
hypophosphorylated RB, which is caused by
inhibition of CDK kinases mediated by p16ink4a and
p21cip1 [49]. Both ES cells and TKO MEFs fail to
arrest in G1 after DNA damage, but they do arrest at
the RB-independent G2/M checkpoint [46,47,50,51].
ES cells, like TKO MEFs, therefore escape from
contact inhibition, are immortal and lack the 
G1 checkpoint. Together, these data strongly 
support the notion that ES cells are not controlled 
by RB in G1.
Cyclin expression and function during G1 in ES cells
What mechanism underlies the functional
inactivation of RB in ES cells? In certain tumour cells
that do not have a mutation in the RB gene,
RB protein is hyperphosphorylated by constitutive
expression of cyclin D/CDK4, cyclin/CDK6 and/or
cyclin E/CDK2 kinases [40,52,53].
Cyclin D1 and cyclin D3 are present in low
amounts in ES cells, whereas cyclin D2 is not
expressed. CDK4-associated kinase activity is
virtually undetectable. The low amount of D-type
cyclins in ES cells reflects the situation in epiblast
cells, which do not express appreciable quantities of
D-type cyclins until gastrulation commences [54]. 
The differentiation of ES or epiblast cells results in
robust expression of D-type cyclins and appreciable
CDK4-associated kinase activity, which signifies the
adoption of G1 regulatory control [10].
Regulation of the basal expression of cyclin D1
differs between ES cells and other cells. First, the
Ras/ERK pathway, which is central to transcriptional
activation of cyclin D1 expression in somatic cells
stimulated by growth factor [55–57], does not
contribute to the expression of cyclin D1 in ES cells [58].
Second, the amount of cyclin D1 protein [59] is
dependent on PI3K signalling, but this seems to be
uncoupled from any specific mitogenic stimulation [58].
Thus, neither PI3K activity nor cyclin D1 expression
is downregulated after serum starvation. 
Taken together, these data lead us to the
conclusion that basal expression of cyclin D1 is
disconnected from mitogenic signals transduced by
tyrosine kinase receptors in ES cells. Constitutive,
albeit low, expression of cyclin D1 could contribute to
constitutive phosphorylation of RB. Alternatively, the
functional significance of cyclin D/CDK4 complexes in
ES cells might be to sequester p27kip1 and prevent this
inhibitor acting on cyclin E/CDK2 kinase [41]. The
resistance to p16ink4a implies, however, that neither
function is essential for ES cell proliferation.
In differentiated cells, enforced expression of
cyclin E is sufficient to overcome growth arrest that is
mediated by p16ink4a. Constitutive cyclin E/CDK2
activity in fibroblasts is also associated with
anchorage-independent growth [60], another
property shown by ES cells. The cyclin E gene is
subject to repression by the active form of RB in
differentiated cells but, as we have discussed above,
the RB pathway seems to be inoperative in ES cells.
Consistent with this, an active form of RB is
undetectable (L. Vitelli and P. Savatier, unpublished)
and cyclin E/CDK2 kinase activity seems to be
constitutive in these cells [10].
Gp130 signalling and cell-cycle control in ES cells
The G1/S transition thus seems to be driven 
uniquely by cyclin E/CDK2 during ES cell
self-renewal. A currently unresolved issue is whether
the apparently constitutive activity of cyclin E/CDK2
is an intrinsic property of ES cells or is dependent on
gp130 signalling.
Withdrawal of LIF induces differentiation of
ES cells rather than cell-cycle arrest. But because
cell-cycle regulation changes early in differentiation,
this does not preclude the possibility that STAT3
could direct the expression of key regulators of the
mitotic cycle in ES cells and stimulate their entry into
S phase. STAT3 can influence G1/S transition in some
types of differentiated cells. In the lymphoid cell line
BAF-03, STAT3 activates expression of specific
cell-cycle regulators including D-type cyclins, p27kip1,
c-Myc and Pim-1 [61]. 
Pim-1 is a serine/threonine kinase that
phosphorylates and activates cdc25A, thereby
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potentiating the accumulation of active 
cyclin E/CDK2 kinase. Myc and Pim-1 combine
synergistically to effect interleukin 6 (IL-6)-dependent
proliferation of BAF cells [62]. Enforced expression of
Myc and Pim-1 is sufficient to overcome cell-cycle
arrest mediated by IL-6 starvation, which indicates
that they are essential targets of STAT3. This
pathway can drive RB hyperphosphorylation and
entry into S phase in the presence of minimal cyclin
D/CDK4 or cyclin D/CDK6 complexes (Fig. 4b).
Although the lack of a reported proliferation
phenotype in ES cells lacking myc or pim-1 seems to
argue against such a mechanism operating in
ES cells, this lack of phenotype could also be
explained by functional redundancy with related
members of these gene families. Data on
transcriptional activity of effectors of G1/S transition
is necessary to determine whether STAT3 
directly stimulates proliferation (Fig. 4b) or 
whether ES cells cycle autonomously until entering
into differentiation.
It is also possible that LIFR or gp130 signalling
could contribute to G1/S transition by recruiting PI3K
through SHP-2 and Gab-1 (Fig. 4b). This pathway has
been identified in the T47D breast cancer cell line, 
in which IL-6 has been shown to control cell 
migration by activating MAPK and PI3K via the
gp130/SHP-2/Gab1 pathway [63]. In ES cells,
LIF-dependent activation of PI3K seems to sustain
cyclin D1 by positively regulating the rate of its
synthesis via p70 S6 kinase and by negatively
regulating the GSK3-dependent rate of protein
degradation [58]. Observations from ES cells lacking
PTEN indicate that PI3K signalling also promotes
degradation of the p27Kip1 inhibitor [31]. These
different actions could result in a low amount of
p27Kip1 that is effectively sequestered by cyclin
D/CDK4 (see above), thereby ensuring that
cyclin E/CDK2 remains constitutively active. 
It should be noted that in the presence of serum 
and feeders, gp130 signalling might not be the only 
or even the most significant activator of PI3K in
cultures of ES cells.
Concluding remarks
As we have discussed above, ES cells have an
unorthodox cell cycle in which the G1 control
pathways that operate in other types of cell 
are reduced or absent. Such features are associated
with the deregulated proliferation of tumour 
cells; however, constitutive replication is also a
common aspect of early embryo development in 
many species. This might simply reflect the
fundamental requirement of establishing sufficient
cell numbers to initiate gastrulation. It is possible,
however, that the uncoupling from G1 regulation
might also be involved in sustaining the
undifferentiated state.
Active hypophosphorylated RB forms 
complexes with and promotes the activity of
differentiation-promoting transcription factors such
as MyoD, myogenin and C/EBP [64–67]. Efficient
hyperphosphorylation and inactivation of RB and its
other family members might therefore be important
to shield pluripotent cells from activities that induce
differentiation. The acquisition of G1/S regulation,
which involves activation of RB, seems to be an early
event in the differentiation of ES cells. Another
possibility is that constitutive transit through G1
could constrain the temporal opportunity for both
chromatin remodelling and the establishment of
heritable transcription programs. Imposition of G1
control might be necessary for the heritable changes
in gene expression that signify cell commitment.
If this were so, then it might explain why ES cells
express RB and components of the Ras/ERK pathway:
their presence would render ES cells poised to
implement G1 regulation immediately on withdrawal
of the self-renewal stimulus.
If the cell-cycle properties of ES cells are
functionally important for pluripotency, then they
should be common to pluripotent human and stem cells
derived from non-human primate embryos [8,68,69]. It
will be instructive to examine whether this is the case,
particularly in light of reports that these cells differ
from mouse ES cells in other respects – most notably
their responsiveness to LIF [70].
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